Do analysts prefer AVTE or PHVS?

Pharvaris has a consensus price target of $59.50, suggesting a potential upside of 56.50%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts plainly believe Pharvaris is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pharvaris 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.79

Which has higher valuation & earnings, AVTE or PHVS?

Pharvaris is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Pharvaris N/A N/A -$198.79M -$3.05 N/A

Is AVTE or PHVS more profitable?

Pharvaris' return on equity of -61.40% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Pharvaris N/A -61.40% -56.00%

Is PVLA or AVTE more profitable?

Palvella Therapeutics' return on equity of -47.84% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -47.84% -38.33% Aerovate Therapeutics N/A -90.19% -77.47%

Do analysts recommend AVTE or MESO?

Mesoblast has a consensus price target of $39.00, suggesting a potential upside of 151.94%. Given Mesoblast's stronger consensus rating and higher probable upside, analysts clearly believe Mesoblast is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is AVTE or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Mesoblast N/A N/A N/A

Do analysts recommend AVTE or KOD?

Kodiak Sciences has a consensus target price of $48.14, suggesting a potential upside of 46.38%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Kodiak Sciences is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has preferable earnings & valuation, AVTE or KOD?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Kodiak Sciences N/A N/A -$229.97M -$4.19 N/A

Is AVTE or KOD more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Kodiak Sciences N/A -273.23% -85.48%

Do analysts rate ADMA or AVTE?

ADMA Biologics presently has a consensus price target of $18.67, indicating a potential upside of 102.24%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Aerovate Therapeutics (AVTE) Competitors

$17.89 -1.25 (-6.53%)

As of 09/11/2026

Compare

AVTE vs. PHVS, PVLA, MESO, KOD, and ADMA

Should you buy Aerovate Therapeutics stock or one of its competitors? Aerovate Therapeutics's main competitors and comparable companies include Pharvaris (PHVS), Palvella Therapeutics (PVLA), Mesoblast (MESO), Kodiak Sciences (KOD), and ADMA Biologics (ADMA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aerovate Therapeutics compare to Pharvaris?

Aerovate Therapeutics (NASDAQ:AVTE) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Pharvaris is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

In the previous week, Pharvaris had 41 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 41 mentions for Pharvaris and 0 mentions for Aerovate Therapeutics. Pharvaris' average media sentiment score of 0.56 beat Aerovate Therapeutics' score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Pharvaris	Positive

Pharvaris' return on equity of -61.40% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Pharvaris	N/A	-61.40%	-56.00%

Pharvaris has a consensus price target of $59.50, suggesting a potential upside of 56.50%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts plainly believe Pharvaris is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.33, meaning that its stock price is 333% less volatile than the broader market.

Summary

Pharvaris beats Aerovate Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Aerovate Therapeutics (NASDAQ:AVTE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Palvella Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

In the previous week, Palvella Therapeutics had 8 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 8 mentions for Palvella Therapeutics and 0 mentions for Aerovate Therapeutics. Palvella Therapeutics' average media sentiment score of 1.32 beat Aerovate Therapeutics' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Palvella Therapeutics	Positive
Aerovate Therapeutics	Neutral

Palvella Therapeutics' return on equity of -47.84% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-47.84%	-38.33%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

40.1% of Palvella Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Palvella Therapeutics currently has a consensus target price of $209.14, suggesting a potential upside of 39.31%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Palvella Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Palvella Therapeutics has higher revenue and earnings than Aerovate Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	50.53	-$41.72M	-$4.83	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Summary

Palvella Therapeutics beats Aerovate Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Mesoblast?

Aerovate Therapeutics (NASDAQ:AVTE) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Mesoblast has a consensus price target of $39.00, suggesting a potential upside of 151.94%. Given Mesoblast's stronger consensus rating and higher probable upside, analysts clearly believe Mesoblast is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Mesoblast had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Mesoblast and 0 mentions for Aerovate Therapeutics. Mesoblast's average media sentiment score of 0.72 beat Aerovate Therapeutics' score of 0.00 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Mesoblast	Positive

Mesoblast's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Mesoblast	N/A	N/A	N/A

1.4% of Mesoblast shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mesoblast has higher revenue and earnings than Aerovate Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Mesoblast	$120.25M	16.72	-$57.50M	-$0.28	N/A

Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market.

Summary

Mesoblast beats Aerovate Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Kodiak Sciences?

Aerovate Therapeutics (NASDAQ:AVTE) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Aerovate Therapeutics' return on equity of -90.19% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Kodiak Sciences	N/A	-273.23%	-85.48%

Kodiak Sciences has a consensus target price of $48.14, suggesting a potential upside of 46.38%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Kodiak Sciences is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

89.1% of Kodiak Sciences shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

In the previous week, Kodiak Sciences had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Kodiak Sciences and 0 mentions for Aerovate Therapeutics. Kodiak Sciences' average media sentiment score of 1.50 beat Aerovate Therapeutics' score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Kodiak Sciences	Positive

Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

Summary

Kodiak Sciences beats Aerovate Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Aerovate Therapeutics compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Aerovate Therapeutics (NASDAQ:AVTE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

ADMA Biologics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

ADMA Biologics presently has a consensus price target of $18.67, indicating a potential upside of 102.24%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, ADMA Biologics had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for ADMA Biologics and 0 mentions for Aerovate Therapeutics. ADMA Biologics' average media sentiment score of 0.85 beat Aerovate Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
ADMA Biologics	Positive
Aerovate Therapeutics	Neutral

ADMA Biologics has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.05	$146.93M	$0.70	13.19
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

75.7% of ADMA Biologics shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ADMA Biologics has a net margin of 32.98% compared to Aerovate Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Summary

ADMA Biologics beats Aerovate Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTE vs. The Competition

Export

Metric	Aerovate Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$518.54M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-5.98	14.18	274.94	25.36
Price / Sales	N/A	1,374.96	685.44	117.05
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	4.52	15.12	10.33	6.20
Net Income	-$75.52M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-10.10%	-4.34%	-3.32%	-2.35%
1 Month Performance	-22.92%	0.54%	-0.53%	-3.23%
1 Year Performance	132.34%	40.74%	23.51%	8.79%

Aerovate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTE Aerovate Therapeutics	N/A	$17.89 -6.5%	N/A	+130.5%	$518.54M	N/A	N/A	20	High Trading Volume
PHVS Pharvaris	3.7252 of 5 stars	$37.84 +7.3%	$53.00 +40.1%	+63.9%	$2.31B	N/A	N/A	30	Trending News Analyst Forecast Insider Trade High Trading Volume
PVLA Palvella Therapeutics	2.53 of 5 stars	$152.28 -3.2%	$209.14 +37.3%	+164.1%	$2.27B	$42.81M	N/A	N/A	Positive News Gap Down
MESO Mesoblast	1.8155 of 5 stars	$16.39 -5.4%	$39.00 +137.9%	+4.5%	$2.25B	$120.25M	N/A	80
KOD Kodiak Sciences	2.1222 of 5 stars	$35.07 -0.8%	$48.14 +37.3%	+255.6%	$2.22B	N/A	N/A	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTE) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aerovate Therapeutics (AVTE) Competitors

AVTE vs. PHVS, PVLA, MESO, KOD, and ADMA

How does Aerovate Therapeutics compare to Pharvaris?

Summary

How does Aerovate Therapeutics compare to Palvella Therapeutics?

Summary

How does Aerovate Therapeutics compare to Mesoblast?

Summary

How does Aerovate Therapeutics compare to Kodiak Sciences?

Summary

How does Aerovate Therapeutics compare to ADMA Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE vs. The Competition

Aerovate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aerovate Therapeutics (AVTE) Competitors

AVTE vs. PHVS, PVLA, MESO, KOD, and ADMA

How does Aerovate Therapeutics compare to Pharvaris?

Which has higher valuation & earnings, AVTE or PHVS?

Does the media favor AVTE or PHVS?

Is AVTE or PHVS more profitable?

Do analysts prefer AVTE or PHVS?

Which has more volatility and risk, AVTE or PHVS?

Summary

How does Aerovate Therapeutics compare to Palvella Therapeutics?

Which has more volatility & risk, PVLA or AVTE?

Does the media favor PVLA or AVTE?

Is PVLA or AVTE more profitable?

Do insiders and institutionals hold more shares of PVLA or AVTE?

Do analysts rate PVLA or AVTE?

Which has stronger valuation & earnings, PVLA or AVTE?

Summary

How does Aerovate Therapeutics compare to Mesoblast?

Do analysts recommend AVTE or MESO?

Does the media refer more to AVTE or MESO?

Is AVTE or MESO more profitable?

Do insiders and institutionals hold more shares of AVTE or MESO?

Which has higher earnings and valuation, AVTE or MESO?

Which has more risk & volatility, AVTE or MESO?

Summary

How does Aerovate Therapeutics compare to Kodiak Sciences?

Is AVTE or KOD more profitable?

Do analysts recommend AVTE or KOD?

Do institutionals & insiders hold more shares of AVTE or KOD?

Which has preferable earnings & valuation, AVTE or KOD?

Does the media refer more to AVTE or KOD?

Which has more volatility & risk, AVTE or KOD?

Summary

How does Aerovate Therapeutics compare to ADMA Biologics?

Which has more risk & volatility, ADMA or AVTE?

Do analysts rate ADMA or AVTE?

Does the media prefer ADMA or AVTE?

Which has better valuation and earnings, ADMA or AVTE?

Do institutionals and insiders believe in ADMA or AVTE?

Is ADMA or AVTE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE vs. The Competition

Aerovate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools